26.88
-1.57(-5.52%)
Currency In USD
Address
3 World Trade Center
New York City, NY 10007
United States of America
Phone
212 784 6595
Website
Sector
Healthcare
Industry
Biotechnology
Employees
93
First IPO Date
January 31, 2025
| Name | Title | Pay | Year Born |
| Mr. Christopher Whitten Bernard | Co-Founder, President, Chief Executive Officer & Director | 763,182 | 1985 |
| Dr. Clive A. Meanwell M.D., Ph.D. | Co-Founder & Executive Chairman | 142,913 | 1958 |
| Mr. Christopher J. Visioli | Co-Founder, Chief Financial Officer & Chief Business Officer | 292,308 | 1977 |
| Dr. Gbolahan Amusa Benz C.F.A., M.D. | EVice President of Strategic Finance & Investor Relations | 496,798 | 1975 |
| Dr. Brian Hubbard Ph.D. | Chief Scientific Officer | 582,969 | 1973 |
| Mr. Paul L. Berns | Co-Founder & Lead Independent Director | 0 | 1967 |
| Ms. Nancye Green | Chief Experience Officer | 0 | N/A |
| Mr. Michael Donovan | Chief Design Officer | 0 | N/A |
| Mr. Matthew Lang J.D. | Chief Legal Officer & Secretary | 0 | 1976 |
| Mr. Daniel Hoey | Chief Technical Operations Officer | 0 | 1967 |
Metsera, Inc., a clinical-stage biotechnology company, develops injectable and oral nutrient stimulated hormone analog peptides to treat obesity, overweight, and related diseases. It develops MET-097i and MET-233i for the treatment of obesity and overweight; MET-233i/MET-097i; and MET-002, MET-224o, MET-067i, and MET-034i to treat disorders, such as diabetes and obesity. The company was incorporated in 2022 and is headquartered in New York, New York.